On Demand 2019 Evolution of Food Allergy Therapies (MOC)
Price: $25 members, $35 non-members
Several new interventions are likely to be approved by the FDA in the upcoming year. These therapies have different levels of efficacy and side effects and will likely greatly impact office flow. Thus, it is imperative that allergists become more facile with their knowledge regarding these therapies.
You can earn up to 1.5 AMA PRA Category 1 Credits™, and up to 1.5 MOC Part II Self-Assessment credits.
- Efficacy and Safety of OIT and EPIT
J. Andrew Bird, MD, FACAAI - Practical Impediments to These New Therapies
Julie Wang, MD, FACAAI - Food Immunotherapy 2.0: What the Future May Hold
Brian P. Vickery, MD
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 1.5 credits as meeting the requirements for MOC Part II Self-Assessment.
Target Audience
- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Nurses and advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals
Learning Objectives
Objective 1:
Differentiate OIT from EPIT in terms of efficacy and safety.
Objective 2:
Understand impediments for implementation of these therapies.
Objective 3:
Identify frequently asked questions regarding these therapies.
J. Andrew Bird, MD, FACAAI
Brian P. Vickery, MD
Julie Wang, MD, FACAAI
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance
- 1.50 CBRN
- 1.50 MOC